THE National Biosafety Board (NBB) met and granted approval for the Institute of Medical Research’s application to conduct a limited mark-release-recapture field trial of the genetically-modified (GM) Aedes aegypti mosquito OX513A(My1) strain early last month.
However, based on the advice of its Genetic Modification Advisory Committee, the approval is subject to the following terms and conditions.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
